Expression of TNFRSF25 on conventional T cells and Tregs.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

1. Targeting TNFRSF25 by agonistic antibodies and multimeric TL1A proteins co-stimulated CD8Journal for immunotherapy of cancer · 2024
   Article
2. The Role of TNFR2 and DR3 in the In Vivo Expansion of Tregs in T Cell Depleting Transplantation Regimens.International journal of molecular sciences · 2020
   Review
3. Mechanism(s) of prolonged attenuation of allergic responses after modulation of idiotypic regulatory network.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2019
   Article
4. Effect of infusion of monoclonal antibodies to tumour necrosis factor-receptor super family 25 on graft rejection in allo-immune mice receiving autologous marrow transplantation.Immunology · 2017
   Article
5. Transient antibody targeting of CD45RC induces transplant tolerance and potent antigen-specific regulatory T cells.JCI insight · 2017
   Article
6. The TNF-family cytokine TL1A: from lymphocyte costimulator to disease co-conspirator.Journal of leukocyte biology · 2015
   Review
7. Immune regulation by CD52-expressing CD4 T cells.Cellular & molecular immunology · 2013
   Article
8. The death receptor 3/TL1A pathway is essential for efficient development of antiviral CD4⁺ and CD8⁺ T-cell immunity.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2012
   Article
9. TL1A and DR3, a TNF family ligand-receptor pair that promotes lymphocyte costimulation, mucosal hyperplasia, and autoimmune inflammation.Immunological reviews · 2011
   Review

Corrections and comments

• Comment on
  Therapeutic Treg expansion in mice by TNFRSF25 prevents allergic lung inflammation.2010

Authors and funding

3 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as